Figure 1From: Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]Mean improvement from baseline in Short Form-36 components at Week 12 in the total (A) and High-Need (B) study populations.Back to article page